AFP and hepatocellular carcinoma: In a prospective study of 734 high-risk Japanese patients with chronic hepatitis or liver cirrhosis, Ishii et al. [28] found that the combination of AFP and PIVKA-II had 65% sensitivity and 85% specificity for detecting early-stage HCC.